COVID-19 Guidance and Information for Healthcare Professionals

Updated August 2023
This page has been automatically translated from English. MSDH has not reviewed this translation and is not responsible for any inaccuracies.

Healthcare Provider Guidance and Resources

Patient Handouts

Vaccination Providers

Reporting COVID-19

COVID-19 Therapeutics

Therapeutics currently authorized or approved for the treatment of mild to moderate COVID-19 include the oral antivirals Paxlovid and Lagevrio and the intravenous antiviral Veklury.
Overview of Therapeutics for the Prevention or Treatment of COVID-19 (

Oral Antivirals

Ordering: The federal government has designed the Healthcare Provider Order Portal (HPOP) for management of COVID-19 therapeutics. Please place your order in HPOP. You will be able to see courses ordered for your site on your HPOP account. If you do not have an HPOP account, please contact

Required reporting:Courses administered (dispensed) and courses available of Paxlovid and Lagevrio should be entered into HPOP by the provider site at least twice per month, on the 15th and last day of the month. Timely and accurate inventory reporting is necessary for federal partners to determine subsequent state allocations.


Therapeutics Locator

Use this interactive map to locate a facility that has one of the authorized therapeutics for COVID-19.

Monoclonal Antibody Therapy

There are no monoclonal antibodies currently authorized in the U.S. for the outpatient treatment of COVID-19.

The following monoclonal antibody products are no longer authorized for use in the U.S.:

  • Bamlanivimab
  • Bamlanivimab/Etesevimab
  • Bebtelovimab
  • Sotrovimab


As of January 26, 2023, Evusheld is no longer authorized for Emergency use for pre-exposure prophylaxis (prevention) of COVID-19.


Remdesivir has been studied in non-hospitalized patients with mild to moderate COVID-19 who are at high risk of progressing to severe disease and is approved by the FDA for use in both hospitalized and non-hospitalized patients.

Ordering: Remdesivir is commercially available and should be ordered through standard pharmaceutical procurement processes.

Health Facilities

Specimen Collection, Delivery and Reporting

Specimen Reporting

SARS-CoV-2 Virus Strain Surveillance

Map and Directions for Laboratory Dropoff

The Dr. F.E.”ED” Thompson, Jr. Public Health Laboratory Facility is on the State Department of Health's central office campus in Jackson, MS at 350 East Woodrow Wilson Drive, Jackson, 39216.

Local Delivery of Samples: Drop samples off at the rear of the Thompson lab building. Detailed instructions are in our sample shipping guidance.

Dropoff hours: Monday through Friday from 8:00–4:30.

CDC Guidance

Healthcare and EMS

Contact Tracing

More from the CDC

Last reviewed on Sep 16, 2022 request edits

Related resources

To view/print PDF documentation you will need Adobe Reader
Mississippi State Department of Health 570 East Woodrow Wilson Dr Jackson, MS 39216 866‑HLTHY4U Contact and information

Facebook Twitter Instagram RSS

Accredited by the national Public Health Accreditation Board